PT  - JOURNAL ARTICLE
AU  - Brim, Hassan
AU  - Moshkovich, Michal
AU  - Figueiredo, Melanie
AU  - Hartung, Emily
AU  - Pizuorno, Antonio
AU  - Hill, Lee
AU  - Popov, Jelena
AU  - Awoyemi, Eyitope Olaide
AU  - Khan, Waliul I
AU  - Oskrochi, Gholamreza
AU  - Ashktorab, Hassan
AU  - Pai, Nikhil
TI  - COVID-19 Patients’ Symptoms: Gastrointestinal Presentations, Comorbidities and Outcomes in a Canadian Hospital Setting
AID  - 10.1101/2021.10.28.21265610
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.28.21265610
4099  - http://medrxiv.org/content/early/2021/10/29/2021.10.28.21265610.short
4100  - http://medrxiv.org/content/early/2021/10/29/2021.10.28.21265610.full
AB  - Background The Coronavirus disease 2019 (COVID-19) pandemic has had significant global impact. While public health interventions and universal health insurance has been credited with minimizing transmission rates in Canada relative to neighboring countries, significant morbidity and mortality have occurred nationwide. We sought to determine factors associated with differences in gastrointestinal outcomes in COVID-19 patients at a Canadian hospital.Methods We collected data from 192 hospital records of COVID-19 patients across seven Hamilton Health Sciences hospitals, a network of academic health centres serving one of the largest metropolitan areas in Canada. Statistical and correlative analysis of symptoms, comorbidities, and mortality were performed.Results There were 192 patients. The mean age was 57.6 years (SD=21.0). For patients who died (n=27, 14%), mean age was 79.2 years old (SD=10.6) versus 54 years for survivors (SD=20.1). There was a higher mortality among patients with older age (p=0.000), long hospital stay (p=0.004), male patients (p=0.032), and patients in nursing homes (p=0.000). Patients with dyspnea (p=0.028) and hypertension (p=0.004) were more likely to have a poor outcome. Laboratory test values that were significant in determining outcomes were an elevated INR (p=0.007) and elevated creatinine (p=0.000). Cough and hypertension were the most common symptom and comorbidity, respectively. Diarrhea was the most prevalent (14.5%) gastrointestinal symptom. Impaired liver function was related to negative outcome (LR 5.6; p=0.018).Conclusions In a Canadian cohort, elevated liver enzymes, prolonged INR and elevated creatinine were associated with poor prognosis. Hypertension was also linked to a higher likelihood of negative outcome.What is already known about this subject?The prevalence of gastrointestinal symptoms in COVID-19 patients across Canada is lackingGastrointestinal manifestations of COVID-19 are well described, and longterm sequelae of gastrointestinal tract involvement are an ongoing concernWhat are the new findings?There was a significant prevalence of gastrointestinal symptoms in patients with a confirmed diagnosis of COVID-19 at one of the largest metropolitan regions across CanadaLiver enzyme abnormalities were common in patients at diagnosisThis report, over an 8-month period, represents the largest cohort of COVID-19 patients reported in CanadaHow might these results impact on clinical practice in the foreseeable future?Baseline gastrointestinal symptoms and laboratory abnormalities correlate with patient outcome in Canadian COVID-19 patientsThese results enhance our knowledge of the prevalence of gastrointestinal symptoms and laboratory abnormalities in Canadian patients and offer important baseline data for longitudinal studies in these patientsOur findings increase our knowledge of the epidemiology of COVID-19 in Canada and allow future comparison with international dataCompeting Interest StatementThe authors have declared no competing interest.Funding Statement1. McMaster University COVID-19 Research Fund (Stream 1) 2. Ontario Ministry of Colleges and Universities COVID-19 Rapid Research Fund (C-127- 2427945-PAI)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Hamilton Integrated Research Ethics Board (Project #: 12862-C) and Howard University Office of Regulatory Research Compliance (IRB-12-CMED-76).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesll data produced in the present study are available upon reasonable request to the authors.